Terms: = Ovarian cancer AND DDX6, P54, 1656, ENSG00000110367, HLR2, P26196, RCK, FLJ36338 AND Treatment
3 results:
1. A Multi-Faceted Analysis Showing
Balcerak A; Szafron LA; Rubel T; Swiderska B; Bonna AM; Konarzewska M; Sołtyszewski I; Kupryjanczyk J; Szafron LM
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673965
[No Abstract] [Full Text] [Related]
2. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
[TBL] [Abstract] [Full Text] [Related]
3. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract] [Full Text] [Related]
